ArticleCancer science2024

Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.

Takashi Matsuoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.